Hospitals, universities, and other institutions participating with MCL.
Name Description
Dartmouth - Coordination and Data Management Group (CDMG) Provides logistic support, data management and protocol development for the biorepository, and conducts statistical and computational research for data analysis.
Johns Hopkins Molecular and Cellular Characterization Laboratory (Prostate) Together this work will yield highly relevant information that can be directly applied to the clinical management of localized prostate cancer. Specifically, it will yield an integrated signature that distinguishes localized - indolent tumors from localized tumors with lethal potential. Additionally we believe these signature will be critical in determining treatment strategies for individuals with prostate cancers of indeterminate kinetics.
JPL Informatics Center NASA/JPL Informatics Center
MD Anderson Cancer Center Molecular and Cellular Characterization Laboratory (Pancreatic) By integrating the amplitude and targets of the host immune response with quantitative physical features obtained using standard-of-care diagnostic imaging studies, we hope to develop reliable algorithms that can predict the risk of progression in pancreatic cysts using relatively non-invasive and portable approaches, and thereby address an unmet need of highest significance to public health.
National Cancer Institute - Division of Cancer Biology
National Cancer Institute - Division of Cancer Prevention
Stanford Molecular and Cellular Characterization Laboratory (Prostate) A systematic study of the events in prostate cancer during its development and evolution will help address the issues of overtreatment by providing prognostic features and biomarkers that help select men for definitive treatment or observation.
UCLA-BU Stanford Molecular and Cellular Characterization Laboratory (Lung) We hypothesize that the pathways underlying heterogeneity in screen-detected lung cancers will be revealed by analysis of molecular (whole exome and mRNA sequencing), microenvironment (immune and inflammatory mediators) and imaging characteristics (semantic and quantitative features) of screen- detected lesions.
UCSF Molecular and Cellular Characterization Laboratory (Breast) Our goal is to identify better ways to screen for and treat the most aggressive cancers and avoid overdiagnosis and overtreatment as well as the inadvertent labeling of indolent lesions as cancers.
University of Vermont Molecular Characterization Laboratory (Breast) The Vermont Breast Cancer Molecular Characterization Laboratory will provide the consortium with scientific leadership, technical resources, and access to a large repository of retrospective and prospectively collected breast specimens linked to the rich data of the VBCSS.
Vanderbilt Molecular and Cellular Characterization Laboratory (Lung) We will be able to build integrated models of ADC behavior, validate a new genomic molecular test on circulating DNA and propose prospective studies that would eventually offer a different intervention based on these predictions i.e. surgery, vs no surgery, adjuvant immuno- or chemotherapy vs no adjuvant therapy and therefore reduce overtreatment and ultimately increase the rate of cure and reduce healthcare cost.